Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603902 · ClinicalTrials.gov registry record · Phase 3
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,008
- Enrollment target
NCT00603902 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 4,008 participants.
The verdict
NCT00603902, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,008 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.
Interventions
- DRUG Matching Placebo
- DRUG Lorcaserin 10 mg once daily (QD)
- DRUG Lorcaserin 10 mg twice a day (BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,008 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00603902
The ClinicalTrials.gov registry entry for NCT00603902 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,008 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Matching Placebo is the first listed.
NCT00603902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00603902 about?
NCT00603902 is a clinical study titled "BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management". The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.
What is the current status of trial NCT00603902?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,008 participants. The study started on 2008-01. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00603902?
The interventions under investigation include: Matching Placebo (DRUG), Lorcaserin 10 mg once daily (QD) (DRUG), Lorcaserin 10 mg twice a day (BID) (DRUG).
Who is sponsoring clinical trial NCT00603902?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.